- Home
- PULM vs ERNA Comparison
PULM vs ERNA Comparison
Compare PULM & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PULM | ERNA |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4M | 7.7M |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PULM | ERNA |
|---|---|---|
| Price | $1.30 | $0.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 74.5K | ★ 1.2M |
| Earning Date | 05-14-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.18 | 31.29 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,910,000.00 | $582,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5069.93 | N/A |
| 52 Week Low | $1.32 | $0.15 |
| 52 Week High | $9.37 | $3.00 |
Technical Indicators
Market Signals| Indicator | PULM | ERNA |
|---|---|---|
| Relative Strength Index (RSI) | 28.66 | 22.58 |
| Support Level | N/A | $0.16 |
| Resistance Level | $4.97 | $0.35 |
| Average True Range (ATR) | 0.15 | 0.03 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 7.80 | 5.56 |
Price Performance
Historical ComparisonAbout PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
About ERNA Eterna Therapeutics Inc.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.